In the iCohort, 130 of 1456 NSCLC patients (8.9%) were confirmed to have KRAS mutations, of whom 42 (32.3%) harbored G12C mutations; there were 304 wildtype patients (excluding EGFR mutation, ALK fusion, ROS1 fusion and BRAF mutation) (Fig. 1b). This evidence concerns the gene ALK and non-small cell lung carcinoma.